EMERGENT BIOSOLUTIONS INC (EBS)

US29089Q1058 - Common Stock

2.85  +0.11 (+4.01%)

Premarket: 2.85 0 (0%)

Fundamental Rating

2

Taking everything into account, EBS scores 2 out of 10 in our fundamental rating. EBS was compared to 597 industry peers in the Biotechnology industry. Both the profitability and financial health of EBS have multiple concerns. EBS has a expensive valuation and it also scores bad on growth.



2

1. Profitability

1.1 Basic Checks

In the past year EBS has reported negative net income.
EBS had a negative operating cash flow in the past year.
EBS had positive earnings in 4 of the past 5 years.
EBS had a positive operating cash flow in 4 of the past 5 years.

1.2 Ratios

With a Return On Assets value of -51.87%, EBS perfoms like the industry average, outperforming 46.78% of the companies in the same industry.
EBS has a worse Return On Equity (-140.85%) than 65.08% of its industry peers.
Industry RankSector Rank
ROA -51.87%
ROE -140.85%
ROIC N/A
ROA(3y)3.9%
ROA(5y)3.37%
ROE(3y)6.7%
ROE(5y)6.26%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Gross Margin of EBS (29.46%) is better than 77.12% of its industry peers.
In the last couple of years the Gross Margin of EBS has declined.
The Profit Margin and Operating Margin are not available for EBS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 29.46%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-14.52%
GM growth 5Y-10.22%

1

2. Health

2.1 Basic Checks

EBS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, EBS has less shares outstanding
The number of shares outstanding for EBS has been increased compared to 5 years ago.
The debt/assets ratio for EBS is higher compared to a year ago.

2.2 Solvency

EBS has an Altman-Z score of 0.17. This is a bad value and indicates that EBS is not financially healthy and even has some risk of bankruptcy.
EBS's Altman-Z score of 0.17 is in line compared to the rest of the industry. EBS outperforms 58.64% of its industry peers.
EBS has a Debt/Equity ratio of 0.64. This is a neutral value indicating EBS is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.64, EBS is not doing good in the industry: 77.12% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.64
Debt/FCF N/A
Altman-Z 0.17
ROIC/WACCN/A
WACC3.75%

2.3 Liquidity

A Current Ratio of 1.09 indicates that EBS should not have too much problems paying its short term obligations.
EBS has a Current ratio of 1.09. This is amonst the worse of the industry: EBS underperforms 89.15% of its industry peers.
EBS has a Quick Ratio of 1.09. This is a bad value and indicates that EBS is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of EBS (0.55) is worse than 94.41% of its industry peers.
Industry RankSector Rank
Current Ratio 1.09
Quick Ratio 0.55

2

3. Growth

3.1 Past

The earnings per share for EBS have decreased strongly by -296.86% in the last year.
EBS shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -16.18%.
EBS shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 14.78% yearly.
EPS 1Y (TTM)-296.86%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q62.2%
Revenue 1Y (TTM)-16.18%
Revenue growth 3Y0.35%
Revenue growth 5Y14.78%
Revenue growth Q2Q12.71%

3.2 Future

The Earnings Per Share is expected to grow by 14.66% on average over the next years. This is quite good.
EBS is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -7.06% yearly.
EPS Next Y-96.04%
EPS Next 2Y63.96%
EPS Next 3Y36.81%
EPS Next 5Y14.66%
Revenue Next Year-3.1%
Revenue Next 2Y-0.09%
Revenue Next 3Y-2.01%
Revenue Next 5Y-7.06%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

3

4. Valuation

4.1 Price/Earnings Ratio

EBS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 1.83, which indicates a rather cheap valuation of EBS.
Based on the Price/Forward Earnings ratio, EBS is valued cheaply inside the industry as 99.49% of the companies are valued more expensively.
EBS's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 21.49.
Industry RankSector Rank
PE N/A
Fwd PE 1.83

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as EBS's earnings are expected to grow with 36.81% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y63.96%
EPS Next 3Y36.81%

0

5. Dividend

5.1 Amount

No dividends for EBS!.
Industry RankSector Rank
Dividend Yield N/A

EMERGENT BIOSOLUTIONS INC

NYSE:EBS (2/26/2024, 7:04:00 PM)

Premarket: 2.85 0 (0%)

2.85

+0.11 (+4.01%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap147.86M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 1.83
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -51.87%
ROE -140.85%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 29.46%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.67
Health
Industry RankSector Rank
Debt/Equity 0.64
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 1.09
Quick Ratio 0.55
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-296.86%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-96.04%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-16.18%
Revenue growth 3Y0.35%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y